PL2726880T3 - Leczenie nowotworu prostaty i sposób określania prognozy dla pacjentów z nowotworem prostaty - Google Patents

Leczenie nowotworu prostaty i sposób określania prognozy dla pacjentów z nowotworem prostaty

Info

Publication number
PL2726880T3
PL2726880T3 PL12807837T PL12807837T PL2726880T3 PL 2726880 T3 PL2726880 T3 PL 2726880T3 PL 12807837 T PL12807837 T PL 12807837T PL 12807837 T PL12807837 T PL 12807837T PL 2726880 T3 PL2726880 T3 PL 2726880T3
Authority
PL
Poland
Prior art keywords
prostate cancer
prognosis
determining
treatment
cancer patients
Prior art date
Application number
PL12807837T
Other languages
English (en)
Inventor
Tommy Andersson
Anders BJARTELL
Original Assignee
Wntresearch Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wntresearch Ab filed Critical Wntresearch Ab
Publication of PL2726880T3 publication Critical patent/PL2726880T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
PL12807837T 2011-07-01 2012-06-28 Leczenie nowotworu prostaty i sposób określania prognozy dla pacjentów z nowotworem prostaty PL2726880T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE1150619 2011-07-01
PCT/SE2012/050738 WO2013006129A1 (en) 2011-07-01 2012-06-28 Treatment of prostate cancer and a method for determining the prognosis for prostate cancer patients
EP12807837.5A EP2726880B1 (en) 2011-07-01 2012-06-28 Treatment of prostate cancer and a method for determining the prognosis for prostate cancer patients

Publications (1)

Publication Number Publication Date
PL2726880T3 true PL2726880T3 (pl) 2019-09-30

Family

ID=47437285

Family Applications (1)

Application Number Title Priority Date Filing Date
PL12807837T PL2726880T3 (pl) 2011-07-01 2012-06-28 Leczenie nowotworu prostaty i sposób określania prognozy dla pacjentów z nowotworem prostaty

Country Status (8)

Country Link
US (1) US9278119B2 (pl)
EP (1) EP2726880B1 (pl)
DK (1) DK2726880T3 (pl)
ES (1) ES2735540T3 (pl)
HU (1) HUE045368T2 (pl)
PL (1) PL2726880T3 (pl)
TR (1) TR201910508T4 (pl)
WO (1) WO2013006129A1 (pl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3229831B1 (en) * 2014-12-10 2020-03-11 Hyperstem SA Methods and compositions for reducing growth, migration and invasiveness of brain cancer stem cells and improving survival of patients with brain tumors
SG11202003613YA (en) * 2017-10-25 2020-05-28 Wntresearch Ab Wnt5a peptides in reduction of cancer stem cells
WO2020053200A1 (en) * 2018-09-10 2020-03-19 Wntresearch Ab Peptides for use in treatment of psoriasis
CN113939305A (zh) * 2019-04-16 2022-01-14 温特研究公司 用于治疗癌症的与免疫检查点抑制剂组合的肽

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601363B1 (fr) 1986-07-08 1988-10-21 Synthelabo (dimethylamino)-2 ethyl) ((((methylthio)-2 phenyl) (phenylmethyl)amino)-2 oxo-2 ethyl) carbamates ou urees, leur preparation et leur application en therapeutique.
WO1998023730A1 (en) * 1996-11-27 1998-06-04 The Penn State Research Foundation Compounds and methods for treating cancer
WO2000031261A2 (en) 1998-11-25 2000-06-02 Cadus Pharmaceutical Corporation Methods and compositions for identifying effectors of the formyl peptide receptor like-1 (fprl-1) receptor
EP1033405A3 (en) 1999-02-25 2001-08-01 Ceres Incorporated Sequence-determined DNA fragments and corresponding polypeptides encoded thereby
AU1700700A (en) 1999-11-05 2001-05-14 Forskarpatent I Syd Ab Compounds, antibodies and methods for treating, preventing or diagnosing tumour metastasis
AU783095B2 (en) 1999-12-07 2005-09-22 Theravance Biopharma R&D Ip, Llc Carbamate derivatives having muscarinic receptor antagonist activity
US7247426B2 (en) 2001-08-02 2007-07-24 Agilent Technologies, Inc. Classifying cancers
JP2006516089A (ja) 2002-10-02 2006-06-22 ジェネンテック・インコーポレーテッド 腫瘍の診断と治療のための組成物と方法
EP1888628B1 (en) 2005-05-30 2014-11-12 Wntresearch AB A peptide ligand to impair cancer cell migration
CN102056939A (zh) * 2008-04-30 2011-05-11 温特研究公司 雌激素受体-α的活性的恢复
AU2009282525A1 (en) 2008-08-13 2010-02-18 Wntresearch Ab The use of Wnt5-a peptide derivates for the treatment of melanoma and gastric cancer
WO2012109540A1 (en) * 2011-02-10 2012-08-16 Fox Chase Cancer Center Methods for inducing epithelial cancer cell senescence

Also Published As

Publication number Publication date
TR201910508T4 (tr) 2019-08-21
HUE045368T2 (hu) 2019-12-30
EP2726880A1 (en) 2014-05-07
WO2013006129A1 (en) 2013-01-10
ES2735540T3 (es) 2019-12-19
US9278119B2 (en) 2016-03-08
US20140206623A1 (en) 2014-07-24
DK2726880T3 (da) 2019-07-15
EP2726880B1 (en) 2019-04-17
EP2726880A4 (en) 2015-03-04

Similar Documents

Publication Publication Date Title
HK1206431A1 (en) Method for the prognosis and treatment of cancer metastasis
HK1254859A1 (zh) 治療乳腺癌的方法
IL233709A (en) A method to predict the likelihood of clinical outcome for a patient with prostate cancer
PL2619576T3 (pl) Środki i sposoby do prognozowania odpowiedzi na leczenie u pacjenta chorego na nowotwór złośliwy
HK1208501A1 (en) Method for the diagnosis, prognosis and treatment of lung cancer metastasis
EP2552415A4 (en) METHODS OF TREATING CANCER
HK1187377A1 (zh) 用於對乳腺癌的轉移進行診斷、預後和治療的方法
EP2788752A4 (en) METHOD FOR SELECTING TREATMENT FOR PATIENTS SUFFERING FROM CANCER
IL220788A (en) Factors associated with cancer treatment and method of preparation
HK1213946A1 (zh) 用於使用 對前列腺癌轉移進行診斷、預後和治療的方法
EP2675485A4 (en) ANTI-MUCIN ANTIBODY FOR THE EARLY RECOGNITION AND TREATMENT OF PANCREATIC CANCER
EP2643001A4 (en) METHOD OF TREATING CANCER
HK1189272A1 (zh) 治療癌症的方法
IL232493A0 (en) A method for quantifying cancer treatment
HRP20160851T1 (hr) Prediktori za liječenje karcinoma
IL228882A0 (en) A method for the treatment of solid malignant tumors, including advanced or metastatic solid malignancies
HRP20181212T1 (hr) Anti-alfa-v integrinsko protutijelo za liječenje raka prostate
SG11201402115TA (en) Methods for diagnosis and/or prognosis of gynecological cancer
EP2640390A4 (en) METHODS OF TREATING CANCER
HUE045368T2 (hu) Prosztatarák kezelése és eljárás prosztatarák páciensek prognózisának meghatározására
HK1200502A1 (en) Method for determining prognosis of prostate cancer in a subject
EP2709730A4 (en) TREATMENT AND PROGNOSIS OF CANCER
EP2560639A4 (en) METHOD FOR THE TREATMENT OF PROSTATE CANCER
EP2721410A4 (en) BIOMARKERS FOR THE DIAGNOSIS AND TREATMENT OF EPITHELIAL CANCER
EP2692358A4 (en) THERAPEUTIC AGENT FOR CANCER, AND METHOD FOR THE PROGNOSTIC DETERMINATION OF CANCER